Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 1.00 |
| ▸ | CA2 | P00918 | 6/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 2/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 12/20 | 0.69 |
| ▸ | PDE4A | P27815 | 10/20 | 0.69 |
| ▸ | PDE4C | Q08493 | 10/20 | 0.69 |
| ▸ | PDE4D | Q08499 | 10/20 | 0.69 |
| ▸ | CA12 | O43570 | 4/20 | 0.50 |
| ▸ | CA9 | Q16790 | 4/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | PDE1A | P54750 | 1/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.48 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tavaborole SCHEMBL596052 | 1.00 | CA1 (1.00) | CA1CA2PDE3APDE4BPDE4A | |
| SCHEMBL19171231 | 1.00 | CA1 (1.00) | CA1CA2PDE3APDE4BPDE4A | |
| Tavaborole SCHEMBL29372574 | 1.00 | CA1 (1.00) | CA1CA2PDE3APDE4BPDE4A | |
| Tavaborole SCHEMBL28132066 | 0.89 | CA1 (0.79) | CA1CA2PDE3APDE4BPDE4A | |
| SCHEMBL19171283 | 0.85 | CA1 (0.72) | CA1CA2PDE3APDE4BPDE4A | |
| SCHEMBL5583464 | 0.85 | CA1 (0.73) | CA1CA2PDE3APDE4BPDE4A | |
| SCHEMBL499993 | 0.85 | CA1 (0.73) | CA1CA2PDE3APDE4BPDE4A | |
| SCHEMBL500220 | 0.83 | CA1 (0.71) | CA1CA2PDE3APDE4BPDE4A | |
| SCHEMBL5583179 | 0.83 | CA1 (0.71) | CA1CA2PDE3APDE4BPDE4A | |
| SCHEMBL2532096 | 0.82 | PDE4B (1.00) | CA1CA2PDE3APDE4BPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 469 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099495-A1 | METHODS OF INHIBITING KLEBSIELLA PNEUMONIAE CARBAPENEMASE-2 | CITY UNIVERSITY OF HONG KONG (CN) | 2025-03-27 | — | — | US | claimed |
| EP-4100413-A1 | ANTIMICROBIAL COMPOUNDS AND COMPOSITIONS | AgroFresh Inc. (US) | 2022-12-14 | — | — | EP | claimed |
| CN-115348965-A | Antimicrobial compounds and compositions | 阿格洛法士公司 | 2022-11-15 | — | — | CN | claimed |
| WO-2021158595-A1 | ANTIMICROBIAL COMPOUNDS AND COMPOSITIONS | AGROFRESH INC. (US) | 2021-08-12 | — | — | WO | claimed |
| CN-106413720-B | Volatile application against pathogens | 阿格洛法士公司 | 2020-09-04 | — | — | CN | claimed |
| US-20200179340-A1 | ANTIFUNGAL AGENTS | F2G LTD (GB) | 2020-06-11 | — | — | US | claimed |
| US-10596150-B2 | Antifungal agents | F2G LIMITED (GB) | 2020-03-24 | — | — | US | claimed |
| US-20190314333-A1 | ANTIFUNGAL AGENTS | F2G LTD (GB) | 2019-10-17 | — | — | US | claimed |
| US-10435419-B2 | Process for the preparation of tavaborole, its novel polymorphic forms and the polymorphs thereof | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2019-10-08 | — | — | US | claimed |
| EP-3261437-B1 | FUNGICIDAL COMPOUNDS AND COMPOSITIONS | AGROFRESH INC (US) | 2019-09-11 | — | — | EP | claimed |
| US-20140213551-A1 | COMPOUNDS AND COMPOSITIONS | DOW AGROSCIENCE LLC (US) | 2014-07-31 | — | — | US | claimed |
| US-8669207-B1 | Compounds and compositions | DOW AGROSCIENCES, LLC. (US) | 2014-03-11 | — | — | US | claimed |
| US-7767657-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2010-08-03 | — | — | US | claimed |
| US-7582621-B2 | Topically treating ungal and periungal infections of the nails, hoofs and claws of mammals by treating with 1-hydroxy-5-fluoro-1,3-dihydro-2,1-benzoxyborole; effectively penetrates the nail; onychomycosis; tinea unguium; fungicides; viricides; bactericides; parasiticides; yeast; microbiocides | ANACOR PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | claimed |
| EP-2066789-A2 | CRYSTAL STRUCTURE OF A TRNA SYNTHETASE | Anacor Pharmaceuticals, Inc. (US) | 2009-06-10 | — | — | EP | claimed |
| EP-1976536-A2 | BORON-CONTAINING SMALL MOLECULES | Anacor Pharmaceuticals, Inc. (US) | 2008-10-08 | — | — | EP | claimed |
| WO-2008070257-A9 | CRYSTAL STRUCTURE OF A TRNA SYNTHETASE | ANACOR PHARMACEUTICALS INC (US) | 2008-09-04 | — | — | WO | claimed |
| WO-2008070257-A2 | CRYSTAL STRUCTURE OF A TRNA SYNTHETASE | ANACOR PHARMACEUTICALS, INC. (US) | 2008-06-12 | — | — | WO | claimed |
| WO-2007078340-A2 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2007-07-12 | — | — | WO | claimed |
| US-20070155699-A1 | Boron-containing small molecules | ANACOR PHARMACEUTICALS (US) | 2007-07-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200179340-A1 | ANTIFUNGAL AGENTS | DPM1, AADAC, PIK3C3 | CA1 1523/4885CA2 132/4885PDE3A 528/4885 |
| US-20070155699-A1 | Boron-containing small molecules | ETF1, POLR1C, DPM1 | CA1 4091/4885CA2 1368/4885PDE3A 4505/4885 |
| US-20140213551-A1 | COMPOUNDS AND COMPOSITIONS | OXA1L, CUL3, CUL2 | CA1 3015/4885CA2 2198/4885PDE3A 1840/4885 |
| US-20190314333-A1 | ANTIFUNGAL AGENTS | DPM1, AADAC, PIK3C3 | CA1 1523/4885CA2 132/4885PDE3A 528/4885 |
| US-10435419-B2 | Process for the preparation of tavaborole, its novel polymorphic forms and the polymorphs thereof | HLA-B, VKORC1L1, VPS4B | CA1 4579/4885CA2 4423/4885PDE3A 3861/4885 |
| US-10596150-B2 | Antifungal agents | DPM1, AADAC, PIK3C3 | CA1 1523/4885CA2 132/4885PDE3A 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.